Author(s): Sunil R Bavaskar, Mayur R. Bhurat

Email(s): bavaskarsunilkumar@gmail.com

DOI: 10.52711/2231-5691.2021.00043   

Address: Mr. Sunil R Bavaskar, Mr. Mayur R. Bhurat
Shri. Prakashchand Jain College of Pharmacy and Research, Palaskhede, Jamner Maharashtra India.
*Corresponding Author

Published In:   Volume - 11,      Issue - 4,     Year - 2021


ABSTRACT:
Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of several hormone-responsive conditions. It was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids, and more recently by the United States' FDA in 2020, under the brand name Orgovyx, for the treatment of advanced prostate cancer. Relugolix has also been studied in the symptomatic treatment of endometriosis. Relugolix is the first (and currently only) orally-administered GnRH receptor antagonist approved for the treatment of prostate cancer-similar therapies such as degarelix require subcutaneous administration-and therefore provides a less burdensome therapeutic option for patients who might otherwise require clinic visits for administration by healthcare professionals.In addition to its relative ease-of-use, relugolix was shown to be superior in the depression of testosterone levels when compared to leuprolide, another androgen deprivation therapy used in the treatment of prostate cancer1,2


Cite this article:
Sunil R Bavaskar, Mayur R. Bhurat. Relugolix is the first and currently only Orally-Administered GnRH Receptor Antagonist Approved for the treatment of Prostate Cancer: A Review. Asian Journal of Pharmaceutical Research. 2021; 11(4):247-0. doi: 10.52711/2231-5691.2021.00043

Cite(Electronic):
Sunil R Bavaskar, Mayur R. Bhurat. Relugolix is the first and currently only Orally-Administered GnRH Receptor Antagonist Approved for the treatment of Prostate Cancer: A Review. Asian Journal of Pharmaceutical Research. 2021; 11(4):247-0. doi: 10.52711/2231-5691.2021.00043   Available on: https://asianjpr.com/AbstractView.aspx?PID=2021-11-4-5


REFERENCES:
1.    www.drug bank.com
2.    Wickstrom M, Nygren P, Larsson R, Harmenberg J, Lindberg J, Sjoberg P, Jerling M, Lehmann F, Richardson P, Anderson K, Chauhan D, Gullbo J: Melflufen-a peptidase-potentiated alkylating agent in clinical trials. Oncotarget. 2017 Jun 8;8(39):66641-66655. doi: 10.18632/oncotarget.18420. eCollection 2017 Sep 12. [PubMed:29029544].
3.    Mateos MV, Blade J, Bringhen S, Ocio EM, Efebera Y, Pour L, Gay F, Sonneveld P, Gullbo J, Richardson PG: Melflufen: A Peptide-Drug Conjugate for the Treatment of Multiple Myeloma. J Clin Med. 2020 Sep 27;9(10). pii: jcm9103120. doi: 10.3390/jcm9103120. [PubMed:32992506]
4.    Barra F, Seca M, Della Corte L, Giampaolino P, Ferrero S (August 2019). "Relugolix for the treatment of uterine fibroids". Drugs Today. 55 (8): 503–512. doi:10.1358/dot.2019.55.8. 3020179. PMID 31461087.
5.    Streuli I, de Ziegler D, Borghese B, Santulli P, Batteux F, Chapron C (March 2012). "New treatment strategies and emerging drugs in endometriosis". Expert Opin Emerg Drugs. 17: 83–104. doi:10.1517/14728214.2012.668885. PMID 22439891. S2CID 27472695
6.    Elancheran, R.; Maruthanila, V. L.; Ramanathan, M.; Kabilan, S.; Devi, R.; Kunnumakara, A.; Kotoky, Jibon (2015). "Recent discoveries and developments of androgen receptor based therapy for prostate cancer". Med. Chem. Commun. 6 (5): 746–768. doi:10.1039/C4MD00416G. ISSN 2040-2503. S2CID 72654573
7.    Tukun FL, Olberg DE, Riss PJ, Haraldsen I, Kaass A, Klaveness J (December 2017). "Recent Development of Non-Peptide GnRH Antagonists". Molecules. 22 (12): 2188. doi:10.3390/molecules 22122188.
8.    Dellis A, Papatsoris A (October 2017). "Therapeutic outcomes of the LHRH antagonists". Expert Rev Pharmacoecon Outcomes Res. 17 (5): 481–488.
9.    Streuli I, de Ziegler D, Borghese B, Santulli P, Batteux F, Chapron C (March 2012). "New treatment strategies and emerging drugs in endometriosis". Expert Opin Emerg Drugs. 17: 83–104.
10.    Elancheran, R.; Maruthanila, V. L.; Ramanathan, M.; Kabilan, S.; Devi, R.; Kunnumakara, A.; Kotoky, Jibon (2015). "Recent discoveries and developments of androgen receptor based therapy for prostate cancer". Med. Chem. Commun. 6 (5): 746–768.

Recomonded Articles:

Author(s): Hiral A. Makadia, Ami Y. Bhatt, Ramesh B. Parmar, Ms. Jalpa S. Paun, H.M. Tank

DOI:         Access: Open Access Read More

Author(s): Prajapati M., Mandloi R., Pillai S, Birla N.

DOI: 10.5958/2231-5691.2020.00021.0         Access: Open Access Read More

Author(s): Rutuja S. Shah, Rutuja R. Shah, Manoj M. Nitalikar, Chandrakant S. Magdum

DOI: 10.5958/2231-5691.2017.00028.4         Access: Open Access Read More

Author(s): Mohd. Yaqub Khan, Maryada Roy, Raj Kumar Rawal, Umesh Kumar Bansal

DOI: 10.5958/2231-5691.2017.00007.7         Access: Open Access Read More

Author(s): Kaustubh V. Gavali, Manohar D. Kengar, Kiran V. Chavan, Vaishnavi P. Anekar, Naziya I. Khan

DOI: 10.5958/2231-5691.2019.00020.0         Access: Open Access Read More

Author(s): Sarika V. Khandbahale

DOI: 10.5958/2231-5691.2019.00021.2         Access: Open Access Read More

Author(s): Ashok Thulluru, Nawaz Mahammed, C. Madhavi, K. Nandini, S. Sirisha, D. Spandana

DOI: 10.5958/2231-5691.2019.00016.9         Access: Open Access Read More

Author(s): Samir K. Shah, Kruti M. Patel, Pinal M. Vaviya

DOI: 10.5958/2231-5691.2017.00014.4         Access: Open Access Read More

Author(s): B. Babu Rao, P. Harish, Saikat Das, T. Ashwin Kumar, V. Raman Koundinya

DOI:         Access: Open Access Read More

Author(s): M. Kranthi Kumar Reddy, B. Narasimha Rao, K. Ravindra Reddy

DOI:         Access: Open Access Read More

Author(s): Jagdish Jadhav, Dharmendra Mundhada, Rajesh Mujoriya

DOI: 10.5958/2231-5691.2015.00019.2         Access: Open Access Read More

Author(s): Zope Janhavi S., Sonawane Pradnya L., Darekar A. B., Saudagar R.B.

DOI: 10.5958/2231-5691.2015.00033.7         Access: Open Access Read More

Author(s): Sarika S. Lokhande

DOI: 10.5958/2231-5691.2019.00015.7         Access: Open Access Read More

Author(s): Bharti Ahirwar

DOI:         Access: Open Access Read More

Asian Journal of Pharmaceutical Research (AJPRes.) is an international, peer-reviewed journal, devoted to pharmaceutical sciences. AJPRes. publishes Original Research Articles, Short Communications..... Read more >>>

RNI: Not Available                     
DOI: 10.5958/2231–5691 


Recent Articles




Tags